A major advance in antimalarial drug discovery has been the shift towards cell-based
phenotypic screening, with notable progress in the screening of compounds against the …

Cerebral malaria occurs due to Plasmodium falciparum infection, which causes 228 million
infections and 450,000 deaths worldwide every year. African people are mostly affected with …

Host genetic factors can confer resistance against malaria, raising the question of whether
this has led to evolutionary adaptation of parasite populations. Here we searched for …

Malaria, a mosquito-borne disease caused by Plasmodium species, claims more than
400,000 lives globally each year. The increasing drug resistance of the parasite renders the …

Antimalarial drugs are becoming less effective due to the emergence of drug resistance.
Resistance has been reported for all available malaria drugs, including artemisinin, thus …

There is a pressing need for compounds with broad-spectrum activity against malaria
parasites at various life cycle stages to achieve malaria elimination. However, this goal …

Malaria remains to be a national and global challenge and priority, as stated in the strategic
plan of the Indonesian Ministry of Health and Sustainable Development Goals. In Indonesia …

The spread of Plasmodium falciparum parasites resistant to most first-line antimalarials
creates an imperative to enrich the drug discovery pipeline, preferably with curative …

Compared to the previous year, there has been an increase of nearly 2 million malaria
cases in 2021. The emergence of drug-resistant strains of Plasmodium falciparum, the most …

The use of antimalarial drugs is an effective strategy in the fight against malaria. However,
selection of drug resistant parasites is a constant threat to the continued use of this …